| Name | XMD-17-51 Trifluoroacetate |
| Description | XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases. |
| In vitro | XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound proficient in modulating an extensive range of protein kinases, such as MPS1 (TTK), ERK5 (BMK1, MAPK7), various polo kinases, Ack1, Ack2, Abl and its mutants, DCAMKL1, ABL1, DCAMKL2, and many others including Bcr-Abl, GAK, cSrc, and Trk family proteins. This versatility renders it applicable in treating a diverse array of diseases, disorders, or conditions [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 8 mg/mL (15.43 mM), Sonication is recommended. H2O : 2 mg/mL (3.86 mM), Sonication is recommended. DMSO : 80 mg/mL (154.29 mM), Sonication is recommended.
|
| Keywords | XMD-17-51 Trifluoroacetate | XMD1751 Trifluoroacetate | XMD 17 51 Trifluoroacetate | NUAK1 | 1628614-50-5 free base | 1628614-50-5 |
| Inhibitors Related | Doxorubicin hydrochloride | Adenosine monophosphate | Adenosine 5'-monophosphate monohydrate | Chromium(III) acetate | Metformin | Methyl cinnamate | Metformin hydrochloride | Tranexamic acid | RMC-7977 | Chitosan oligosaccharide | Isovaleric acid | MK8722 |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Anti-Obesity Compound Library | Anti-Ovarian Cancer Compound Library | Autophagy Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |